Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 313

Sort by

Sort Order Select

Journal Articles

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers

Debra D. Pittman, Patrick C. Hines, David Beidler, Denis Rybin, Andrew L. Frelinger, III, Alan D. Michelson, Ke Liu, Xiufeng Gao, Jennell White, Ahmar U. Zaidi, Robert J. Charnigo, Michael U. Callaghan

Blood (2021) 137 (15): 2010–2020.

https://doi.org/10.1182/blood.2020006020

Published: 2021

Includes: Supplemental data

Journal Articles

Using patient-reported outcomes to improve survivorship care

Lindsay M. Morton, Betty K. Hamilton

Blood (2020) 135 (21): 1819–1820.

https://doi.org/10.1182/blood.2020005881

Published: 2020

Journal Articles

Patient-reported outcomes in survivors of childhood hematologic malignancies with hematopoietic stem cell transplant

Hsiu-Ju Yen, Hesham M. Eissa, Neel S. Bhatt, Sujuan Huang, Matthew J. Ehrhardt, Nickhill Bhakta, Kirsten K. Ness, Kevin R. Krull, D. Kumar Srivastava, Leslie L. Robison, Melissa M. Hudson, I-Chan Huang

Blood (2020) 135 (21): 1847–1858.

https://doi.org/10.1182/blood.2019003858

Published: 2020

Includes: Supplemental data

Journal Articles

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

David Cella, PhD, Ellen K. Ritchie, MD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3850.

https://doi.org/10.1182/blood-2019-123790

Published: 2019

Journal Articles

A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Max S. Topp, MD, Johannes Duell, MD, Jingjin Li, PhD, Vladimir Jankovic, MD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Lieve Adriaens, PharmD, Mary Peterman, PharmD, Srikanth R. Ambati, MBBS, MD, Rajat Bannerji, MD PhD

Blood (2019) 134 (Supplement_1): 4007.

https://doi.org/10.1182/blood-2019-126670

Published: 2019

Journal Articles

A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma

Jason R. Westin, MD, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Hun Ju Lee, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Raphael E Steiner, MD, Sairah Ahmed, MD, Simrit Parmar, MBBS, Ranjit Nair, MBBS,MD, Rebecca Harrison, MD, Luis Fayad, MD

Blood (2019) 134 (Supplement_1): 4086.

https://doi.org/10.1182/blood-2019-131463

Published: 2019

Journal Articles

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

Donald L. Patrick, Annette Powers, Monika Parisi, Yeonhee Kim, Jacob Garcia, MD, Christine Dehner, David G. Maloney, MD PhD

Blood (2019) 134 (Supplement_1): 66.

https://doi.org/10.1182/blood-2019-127145

Published: 2019

Journal Articles

Rapid Improvement of Patient-Reported Outcomes with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated CLL and Coexisting Conditions: A Prospective Analysis from the CLL14 Trial

Othman Al-Sawaf, MD, Brittany Gentile, PhD, Jacob Devine, MA, Kavita Sail, PhD, Maneesh Tandon, MD, Anna-Maria Fink, MD, Nadine Kutsch, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD

Blood (2019) 134 (Supplement_1): 4305.

https://doi.org/10.1182/blood-2019-126542

Published: 2019

Journal Articles

Predictors of the Rowland Universal Dementia Assessment Scale (RUDAS) Performance in Adults with Sickle Cell Disease

Stéphanie Forté, MD MSc, FRCPC, Florence Blais, Mathias Castonguay, Nafanta Fadiga, Richard Ward, MSc, MRCP, FRCPath, Béland Sébastien, PhD, Melanie Cohn, PhD CPsych, Denis Soulières, MD, Kevin H. M. Kuo, MDMSc,FRCPC

Blood (2019) 134 (Supplement_1): 2294.

https://doi.org/10.1182/blood-2019-129342

Published: 2019

Journal Articles

Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase IIb Trial

Blood (2019) 134 (Supplement_1): 2843.

https://doi.org/10.1182/blood-2019-126661

Published: 2019

Journal Articles

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Steffen Koschmieder, Susanne Isfort, Dominik Wolf, Univ. Prof. Dr., Florian H. Heidel, Philippe Schafhausen, Martin Griesshammer, MD, Denise Wolleschak, Uwe Platzbecker, Konstanze Döhner, Philipp J. Jost, MD, Stefani B. Parmentier, Nikolas von Bubnoff, Frank Stegelmann, MD, Angela Maurer, Jeremy Franklin, Martina Crysandt, MD, Deniz Gezer, Martin Hellmich, Tim H Brümmendorf, MD

Blood (2019) 134 (Supplement_1): 2944.

https://doi.org/10.1182/blood-2019-123985

Published: 2019

Journal Articles

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Francesco Passamonti, MD, Lynda Foltz, MD FRCPC, David M Ross, MD PhD, Nicola Vianelli, MD, Alessandro M. Vannucchi, MD, Norio Komatsu, MD PhD, Pierre Zachée, Ranjan Tiwari, MSc, Evren Zor, MD, Shalini Chaturvedi, Geralyn Gilotti, MSc, Francisco Cervantes, MD

Blood (2019) 134 (Supplement_1): 2952.

https://doi.org/10.1182/blood-2019-124739

Published: 2019

Journal Articles

One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B

Steven Pipe, MD, Adam Giermasz, MD PhD, Giancarlo Castaman, MD, Nigel S. Key, MBChB, FRCP, Susan U Lattimore, Frank Leebeek, MD PhD, Wolfgang Miesbach, MD PhD, Michael Recht, MD PhD, Esteban Gomez, MD, Alison Long, Robert Gut, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 3348.

https://doi.org/10.1182/blood-2019-128765

Published: 2019

Journal Articles

Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone

Cristina Gasparetto, MD, Rakesh Popat, Shaji K. Kumar, MD, Michele Cavo, Javier de la Rubia, MD PhD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, James Maciel, Liang-Tsai Hsiao, Philippe Moreau, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Jia Jia, PhD MBA, Sudeep Karve, PhD, Esprit Ma, Jacob Devine, MA, Katy Benjamin

Blood (2019) 134 (Supplement_1): 3177.

https://doi.org/10.1182/blood-2019-127387

Published: 2019

Journal Articles

Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect ® MM Registry

Hans C. Lee, MD, Sikander Ailawadhi, MD, Cristina Gasparetto, MD, Sundar Jagannath, Robert M. Rifkin, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, James W. Hardin, PhD, Lynne I. Wagner, PhD, James L. Omel, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 3129.

https://doi.org/10.1182/blood-2019-126205

Published: 2019

Journal Articles

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Matthew Jenner, MBBS, MRCP, FRCPath, Amy L Sherborne, PhD, Andrew Hall, Vallari Shah, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, James Croft, MBBS, BSc, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Louise Flanagan, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Ruth M De Tute, BSc,MSc, Roger G. Owen, MD, Guy Pratt, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 3162.

https://doi.org/10.1182/blood-2019-123547

Published: 2019

Journal Articles

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

Jennifer R Brown, MD PhD, Barbara F. Eichhorst, MD, Paolo Ghia, MD PhD, Arnon P. Kater, MD PhD, Jianyong Li, MD, Sudha Khurana, Mostafa Elhamy, Min Hui Wang, PhD, John F. Seymour, MBBS, PhD FRACP

Blood (2019) 134 (Supplement_1): 4318.

https://doi.org/10.1182/blood-2019-123057

Published: 2019

Journal Articles

Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study

Johannes Oldenburg, María Teresa Alvarez Román, Giancarlo Castaman, Maissaa Janbain, MD, Tadashi Matsushita, Karina Meijer, Sabine Friedl, Martin Sanabria, Mark Reding

Blood (2019) 134 (Supplement_1): 4943.

https://doi.org/10.1182/blood-2019-128140

Published: 2019

Journal Articles

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy

Merav Bar, MD, Julia Ruark, MD MPH, Erin Mullane, DNP, Nancy Cleary, BSc, Ana Cordeiro, MD, Evandro D. Bezerra, MD, Jenna M. Voutsinas, MPH, Bronwen E. Shaw, MD PhD, Qian Vicky Wu, PhD, Kathryn E Flynn, PhD, Stephanie J. Lee, MD MPH, Cameron J. Turtle, MBBS, PhD, David G. Maloney, MD PhD, Jesse Fann

Blood (2019) 134 (Supplement_1): 4453.

https://doi.org/10.1182/blood-2019-122755

Published: 2019

Journal Articles

Quality of Life Impairment in Adult Patients with ACUTE Lymphoblastic Leukemia with Minimal Residual Disease in France

Stephane Lepretre, MD, Chantal Touboul, Alain Flinois, PhD, Lucie Kutikova, PhD, Kahina Makhloufi, MD, Jean-Vannak Chauny, PharmD, Gaëlle Désaméricq

Blood (2019) 134 (Supplement_1): 5123.

https://doi.org/10.1182/blood-2019-122466

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers

Using patient-reported outcomes to improve survivorship care

Patient-reported outcomes in survivors of childhood hematologic malignancies with hematopoietic stem cell transplant

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

Rapid Improvement of Patient-Reported Outcomes with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated CLL and Coexisting Conditions: A Prospective Analysis from the CLL14 Trial

Predictors of the Rowland Universal Dementia Assessment Scale (RUDAS) Performance in Adults with Sickle Cell Disease

Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase IIb Trial

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome

One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B

Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone

Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect ® MM Registry

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy

Quality of Life Impairment in Adult Patients with ACUTE Lymphoblastic Leukemia with Minimal Residual Disease in France

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only